Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions

Archives of Neurology

Volumn 64, Issue 2, 2007, Pages 169-176

  Stüve, Olaf ^a,b,c,d   Marra, Christina M ^e   Cravens, Petra D ^b   Singh, Mahendra P ^b   Hu, Wei ^b   Lovett Racke, Amy ⁱ   Monson, Nancy L ^b,c   Phillips, J Theodore ^f   Cohen Tervaert, Jan W ^g   Nash, Richard A ^h   Hartung, Hans Peter ^d   Kieseier, Bernd C ^d   Racke, Michael M ⁱ   Frohman, Elliot M ^b   Hemmer, Bernhard ^d  

^a Veterans Affairs North Texas Health Care System   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Multiple Sclerosis Center at Texas Neurology   (United States)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISERUM; ANTIVIRUS AGENT; BETA INTERFERON; CIDOFOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2; NATALIZUMAB; RECOMBINANT ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; RECOMBINANT VERY LATE ACTIVATION ANTIGEN 4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIVIRAL THERAPY; ARTHRALGIA; BINDING AFFINITY; BLOOD AUTOTRANSFUSION; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; DIAPHORESIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GLIA CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; JC VIRUS; KIDNEY FAILURE; LEUKAPHERESIS; LEUKOCYTE TRANSFUSION; LEUKOCYTOSIS; LYMPHOMA; MALAISE; MULTIPLE SCLEROSIS; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; SYNCOPE; THORAX PAIN; THROMBOSIS; TREATMENT OUTCOME; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS, INTRAVENOUS; INTEGRINS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RNA, SMALL INTERFERING;

EID: 33846969181     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.2.169     Document Type: Review

References (83)

1. Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336-1342.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-923.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
4. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-381.
5. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-374.
6. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368.
7. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-933.
8. Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148:1477-1479.
9. Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147:676-684.
10. Demeter LM. JC, BK, and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. New York, NY: Churchill Livingstone; 1995:1400-1406.
11. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973;127:467-470.
12. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: a review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107:78-87.
13. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(suppl 2):S180-S186.
14. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol. 1992;31:454-462.
15. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70:7004-7012.
16. Azzi A, De Santis R, Ciappi S, et al. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol. 1996;2:411-416.
17. Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Vago L, Boldorini R, Costanzi G. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. J Med Virol. 1995;47:219-225.
18. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 2005;40:738-744.
19. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743-747.
20. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63:1383-1387.
21. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999;52:1072-1074.
22. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12:1149-1154.
23. Antinori A, Ammassari A, Giancola ML, et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol. 2001;7:323-328.
24. Koralnik IJ, Du Pasquier RA, Kuroda MJ, et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol. 2002;168:499-504.
25. Du Pasquier RA, Clark KW, Smith PS, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol. 2001;7:318-322.
26. Du Pasquier RA, Kuroda MJ, Schmitz JE, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol. 2003;77:11918-11926.
27. + T cell help. J Exp Med. 1997;186:65-70.
28. Fong IW, Toma E; Canadian PML Study Group. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis. 1995;20:1305-1310.
29. von Einsiedel RW, Fife TD, Aksamit AJ, et al. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol. 1993;240:391-406.
30. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
31. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
32. Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol. 1994;4:857-867.
33. Andersson K, Choulier L, Hamalainen MD, van Regenmortel MH, Altschuh D, Malmqvist M. Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. J Mol Recognit. 2001;14:62-71.
34. Leckband DE, Kuhl TL, Wang HK, Muller W, Herron J, Ringsdorf H. Force probe measurements of antibody-antigen interactions. Methods. 2000;20:329-340.
35. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
36. Hogg N, Laschinger M, Giles K, McDowall A. T-cell integrins: more than just sticking points. J Cell Sci. 2003;116:4695-4705.
37. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol. 1998;4:451-456.
38. Hall CD, Dafni U, Simpson D, et al; AIDS Clinical Trials Group 243 Team. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med. 1998;338:1345-1351.
39. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791-1797.
40. Przepiorka D, Jaeckle KA, Birdwell RR, et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 1997;20:983-987.
41. Buckanovich RJ, Liu G, Stricker C, et al. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol. 2002;81:410-413.
42. Re D, Bamborschke S, Feiden W, et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant. 1999;23:295-298.
43. Kunschner L, Scott TF. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology. 2005;65:1510.
44. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380-1383.
45. Huang SS, Skolasky RL, Dal Pan GJ, Royal W III, McArthur JC. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol. 1998;4:324-332.
46. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol. 2001;7:353-357.
47. Nath A, Venkataramana A, Reich DS, Cortese I, Major EO. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology. 2006;66:149-150.
48. Khoury H, Adkins D, Brown R, et al. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25:1197-1201.
49. Alvarado Ibarra ML, Borbolla E Jr, Lopez-Hernandez MA, et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Rev Invest Clin. 1999;51:77-80.
50. Grzegorzewski KJ, Komschlies KL, Jacobsen SE, Ruscetti FW, Keller JR, Wiltrout RH. Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7. J Exp Med. 1995;181:369-374.
51. Alpdogan O, Schmaltz C, Muriglan SJ, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001;98:2256-2265.
52. Storek J, Gillespy T III, Lu H, et al. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood. 2003;101:4209-4218.
53. Lu H, Zhao Z, Kalina T, et al. Interleukin-7 improves reconstitution of antiviral CD4 T cells. Clin Immunol. 2005;114:30-41.
54. Openshaw H, Stüve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54:2147-2150.
55. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol. 2003;9(suppl 1):25-31.
56. Bokemeyer C, Schmoll HJ, Harstrick A. Side-effects of GM-CSF treatment in advanced testicular cancer. Eur J Cancer. 1993;29A:924.
57. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
58. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004;44:1945-1956.
59. Nadav L, Gur AY, Korczyn AD, Bornstein NM. Stroke in hospitalized patients: are there special risk factors? Cerebrovasc Dis. 2002;13:127-131.
60. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders, part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63:930-935.
61. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders, part 2: treatment of neuromuscular disorders. Arch Neurol. 2006;63:1066-1071.
62. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002:CD002275.
63. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34:480-485.
64. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2002:CD001798.
65. Carter JL, Agius M, Mass M, et al. A placebo-controlled, pharmacodynamic, pharmacokinetic, tolerability and safety study of three doses of intravenous natalizumab in multiple sclerosis [abstract]. Neurology. 2000;54(suppl 3):A259.
66. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51:S2-S8.
67. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol. 1999;56:661-663.
68. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284-288.
69. Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation. 1997;64:1847-1850.
70. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535-542.
71. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 1996;97:865-869.
72. Price TH, Dale DC. Neutrophil transfusion: effect of storage and of collection method of neutrophil blood kinetics. Blood. 1978;51:789-798.
73. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46:422-433.
74. Lovett-Racke AE, Cravens PD, Gocke AR, Racke MK, Stüve O. Therapeutic potential of small interfering RNA for central nervous system diseases. Arch Neurol. 2005;62:1810-1813.
75. Suh IS, Shaffer MF. Intracerebral Salmonella typhosa infection in chicks: passive protection by chicken antisera of differing specificities. J Immunol. 1965;95:567-573.
76. Cowan KM. Immunochemical studies of foot-and-mouth disease, IV: preparation and evaluation of antisera specific for virus, virus protein sub-unit and the infection-associated antigen. J Immunol. 1968;101:1183-1191.
77. Fujiwara K, Kitagawa T. Specificity and use of antisera produced against anticancer drugs. Adv Immun Cancer Ther. 1986;2:251-292.
78. Kitagawa T, Bai G, Fujiwara K. Specificities of five kinds of antisera produced against crude drugs, pinella tuber, hoelen, glycyrrhizae radix, trichosanthes root and panax ginseng. Biol Pharm Bull. 1996;19:335-340.
79. Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80:279-281.
80. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457-462.
81. Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol. 2005;4:403-412.
82. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
83. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403-1408.